Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
BioNTech SE
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Inhibrx Biosciences, Inc
Bicara Therapeutics
University of Erlangen-Nürnberg Medical School
National Cancer Institute (NCI)